Edition:
United Kingdom

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

4.00USD
20 Apr 2018
Change (% chg)

$-0.20 (-4.76%)
Prev Close
$4.20
Open
$4.25
Day's High
$4.25
Day's Low
$3.97
Volume
31,057
Avg. Vol
56,847
52-wk High
$5.40
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

COMPUGEN REPORTS Q3 LOSS PER SHARE $0.19
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS THIRD QUARTER 2017 RESULTS.Q3 LOSS PER SHARE $0.19.‍AS OF SEPTEMBER 30, 2017, CASH AND CASH RELATED ACCOUNTS TOTALED $38.5 MILLION, COMPARED WITH $61.5 MILLION AS OF DECEMBER 31, 2016​.  Full Article

Compugen to initiate manufacturing of COM902
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Compugen Ltd :Compugen Ltd - ‍advancing COM902 into manufacturing in anticipation of filing an investigational new drug (IND) application in 2019​.Compugen Ltd - ‍entered into process development and manufacturing service agreement with Bayer Healthcare LLC (Bayer) to produce COM902.Compugen Ltd - ‍working towards filing IND for COM902 in 2019​.  Full Article

Compugen files for mixed shelf of up to $200 million
Tuesday, 9 Aug 2016 

Compugen Ltd :Files for mixed shelf of upto $200 million - SEC filing.  Full Article

Compugen says discloses lead therapeutic candidate for CGEN-15029 immuno-oncology program
Wednesday, 22 Jun 2016 

Compugen : Discloses Lead Therapeutic Candidate For Cgen-15029 immuno-oncology program .Ind filing for com701 anticipated next year.  Full Article

Compugen reports Q1 loss of $0.17 per share
Tuesday, 10 May 2016 

Compugen Ltd : Compugen ltd. Reports first quarter 2016 financial results . Q1 loss per share $0.17 .Q1 revenue $100,000.  Full Article

BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018

* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)